

Status: Currently Official on 16-Feb-2025  
Official Date: Official as of 01-Aug-2021  
Document Type: USP Monographs  
DocId: GUID-B849B68C-4EF6-4DF8-8B6C-24C246F6925D\_2\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M72395\\_02\\_01](https://doi.org/10.31003/USPNF_M72395_02_01)  
DOI Ref: 98x6d

© 2025 USPC  
Do not distribute

## Quazepam Tablets

» Quazepam Tablets contain not less than 90 percent and not more than 110.0 percent of quazepam ( $C_{17}H_{11}ClF_4N_2S$ ).

**Packaging and storage**—Preserve in a well-closed container.

**Change to read:**

**USP REFERENCE STANDARDS (11)**—

[USP Ethylparaben RS](#)

[USP Quazepam RS](#)

[USP Quazepam Related Compound A RS](#)

7-Chloro-▲5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)▲ (ERR 1-Aug-2021) -2H-1,4-benzodiazepine-2-one.

**Identification**—

**A:** The retention time of the major peak in the chromatogram of the *Assay preparation* corresponds to that in the chromatogram of the *Standard preparation*, both relative to the internal standard as obtained in the *Assay*.

**B:** The  $R_F$  value of the principal spot in the chromatogram of the *Test solution* obtained in the test for *Related compounds* corresponds to that in the chromatogram of *Standard solution A*.

**Dissolution (711)**—

*Medium*: 1% sodium lauryl sulfate; 900 mL.

*Apparatus 2*: 50 rpm.

*Time*: 30 minutes.

*Procedure*—Determine the amount of  $C_{17}H_{11}ClF_4N_2S$  dissolved from UV absorbances at the wavelength of maximum absorbance at about 287 nm on filtered portions of the solution under test in comparison with a *Standard solution* having a known concentration of [USP Quazepam RS](#) dissolved in a small volume of methanol and diluted with *Dissolution Medium*.

*Tolerances*—Not less than 80% (Q) of the labeled amount of  $C_{17}H_{11}ClF_4N_2S$  is dissolved in 30 minutes.

**Uniformity of Dosage Units (905)**: meet the requirements.

**Related compounds**—

*Test solution*—Grind 10 Tablets to a fine powder. Dissolve an accurately weighed portion of the powder in methylene chloride to obtain a solution having a concentration of 10 mg of quazepam per mL. Mix for 30 minutes, and centrifuge.

*Standard solution A*—Dissolve an accurately weighed quantity of [USP Quazepam RS](#) in methylene chloride to obtain a solution having a known concentration of about 10 mg per mL.

*Standard solution B*—Dissolve an accurately weighed quantity of [USP Quazepam RS](#) in methylene chloride to obtain a solution having a known concentration of about 0.04 mg per mL (0.2%).

*Standard solution C*—Dissolve an accurately weighed quantity of [USP Quazepam Related Compound A RS](#) in methylene chloride to obtain a solution having a known concentration of about 0.3 mg per mL (1.5%).

*Procedure*—Separately apply 10  $\mu$ L each of the *Test Solution* and *Standard solution A* and 5  $\mu$ L each of *Standard solutions B* and *C* to a thin-layer chromatographic plate (see [Chromatography \(621\)](#)) coated with a 0.25-mm layer of chromatographic silica gel. Allow the spots to dry, and develop the chromatogram in a solvent system consisting of a mixture of cyclohexane, ethyl acetate, and ether (170:40:25) in a paper-lined tank until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, mark the solvent front, allow to air-dry, and examine the plate under short-wavelength UV light. Compare the intensity of the secondary spot in the chromatogram of the *Test solution* having the same  $R_F$  value as the principal spot in the chromatogram of *Standard solution C*. The spot is not larger or more intense than the principal spot obtained from *Standard solution C*. Compare the intensities of any additional secondary spots observed in the chromatogram of the *Test solution* with that of the principal spot in the chromatogram of *Standard solution B*: no additional secondary spot from the chromatogram of the *Test solution* is larger or more intense than the principal spot obtained from *Standard solution B*, and the sum of the intensities of the additional secondary spots obtained from the *Test solution* is not more than 0.6%.

**Assay**—

*Mobile phase*—Prepare a filtered and degassed mixture of methanol and water (7:3). Make adjustments, if necessary (see *System Suitability under Chromatography (621)*).

*Internal standard solution*—Dissolve an accurately weighed quantity of [USP Ethylparaben RS](#) in methanol, and dilute quantitatively, and stepwise if necessary, with methanol to obtain a solution containing about 0.19 mg per mL.

*Standard preparation*—Dissolve an accurately weighed quantity of [USP Quazepam RS](#) in *Internal standard solution*, and dilute quantitatively, and stepwise if necessary, with *Internal standard solution* to obtain a solution having a known concentration of about 1.5 mg of quazepam per mL.

*Assay preparation*—Weigh and finely powder not fewer than 10 Tablets. Transfer an accurately weighed portion of powder, equivalent to about 15 mg of quazepam, to a 50-mL screw-capped centrifuge tube. Add 10.0 mL of *Internal standard solution*, and centrifuge for 30 minutes.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L7. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between ethylparaben and quazepam is not less than 5.5; and the relative standard deviation for replicate injections is not more than 2.0%. [NOTE—For identification purposes, the relative retention times are about 0.4 for ethylparaben and 1.0 for quazepam.]

*Procedure*—Separately inject equal volumes (about 5  $\mu$ L) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of quazepam ( $C_{17}H_{11}ClF_4N_2S$ ) in the portion of Tablets taken by the formula:

$$10C(R_u/R_s)$$

in which *C* is the concentration, in mg per mL, of [USP Quazepam RS](#) in the *Standard preparation*; and  $R_u$  and  $R_s$  are the ratios of the peak response of quazepam to that of ethylparaben obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
QUAZEPAM TABLETS	<a href="#">Documentary Standards Support</a>	SM42020 Small Molecules 4
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM42020 Small Molecules 4

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 32(2)

**Current DocID: GUID-B849B68C-4EF6-4DF8-8B6C-24C246F6925D\_2\_en-US**

**DOI: [https://doi.org/10.31003/USPNF\\_M72395\\_02\\_01](https://doi.org/10.31003/USPNF_M72395_02_01)**

**DOI ref: [98x6d](#)**